Clinical Trials

20 enrolled

Multiple Myeloma

NCT05336383 2026-04-15

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

30 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07107529 2026-04-15

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

150 enrolled

Multiple Myeloma

NCT03412877 2026-04-14

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT06103838 2026-04-14

18F-Fluciclovine PET/CT in Multiple Myeloma

60 enrolled

Multiple Myeloma

NCT07382739 2026-04-14

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

34 enrolled

Multiple Myeloma

NCT04634552 2026-04-13

MonumenTAL-1

510 enrolled 2 FDA

Multiple Myeloma, Hematologic Neoplasms

NCT06179888 2026-04-13

Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma

78 enrolled

Multiple Myeloma

NCT06483100 2026-04-13

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance

65 enrolled

Multiple Myeloma

NCT06500884 2026-04-13

Talisman

210 enrolled

Multiple Myeloma

NCT07149857 2026-04-13

CARTITUDE-10

60 enrolled

Multiple Myeloma

NCT07266441 2026-04-13

TRIlogy-3

157 enrolled

Multiple Myeloma

NCT06140524 2026-04-08

LINKER-MGUS1

116 enrolled

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

NCT05969860 2026-04-03

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

220 enrolled

MyeloidPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes

NCT07509086 2026-04-03

IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia

25 enrolled

Leukemia, Plasma Cell, Multiple Myeloma

NCT02693535 2026-04-02

TAPUR

4,200 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms

NCT05898646 2026-03-30

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

96 enrolled

Immunoglobulin Light-chain Amyloidosis

NCT03297606 2026-03-27

CAPTUR

720 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT07489534 2026-03-24

Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction

25 enrolled

Multiple Myeloma, Renal Insufficiency

NCT05405387 2026-03-20

IMPACT

120 enrolled

Leukemia, Plasma Cell, Multiple Myeloma

NCT05272826 2026-03-18

BOREALIS

75 enrolled

Multiple Myeloma

NCT06138275 2026-03-13

Elranatamab in R/R Multiple Myeloma

32 enrolled

Multiple Myeloma

NCT06832865 2026-03-12

ELISA in Relapsed/Refractory MM

30 enrolled

Multiple Myeloma, Recurrence

NCT07284758 2026-03-12

MOMENTUM

Multiple Myeloma

NCT05896228 2026-03-11

Iber-KDd

30 enrolled

Multiple Myeloma

NCT06976476 2026-03-11

Study of IgPro20 to Prevent Infection in People With Multiple Myeloma and Hypogammaglobulinemia

Agammaglobulinemia, Multiple Myeloma, Common Variable Immunodeficiency

NCT07454382 2026-03-06

A Study of Elranatamab and Cyclophosphamide in People With Multiple Myeloma

26 enrolled

Multiple Myeloma

NCT05091372 2026-03-05

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

94 enrolled

Multiple Myeloma

NCT06066346 2026-03-04

A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

17 enrolled

Multiple Myeloma

NCT05870917 2026-03-02

A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

20 enrolled

Leukemia, Plasma Cell

NCT05344833 2026-02-23

HEME-18

50 enrolled

Multiple Myeloma

NCT05530421 2026-02-23

SELVEDge

33 enrolled

Multiple Myeloma, Recurrence

NCT05972135 2026-02-23

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

Cytokine Release Syndrome, Multiple Myeloma

NCT06100237 2026-02-23

REVIVE

50 enrolled

Multiple Myeloma

NCT06711705 2026-02-20

Elranatamab in Relapsed/Refractory Multiple Myeloma

33 enrolled

Multiple Myeloma

NCT06207799 2026-02-19

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

40 enrolled

Multiple Myeloma

NCT06679829 2026-02-19

A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell Transplant

215 enrolled

Multiple Myeloma

NCT06015542 2026-02-10

ERICA

20 enrolled

Multiple Myeloma

NCT06297226 2026-02-10

QUINTESSENTIAL

230 enrolled

Multiple Myeloma, Recurrence

NCT06940297 2026-02-06

Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

44 enrolled

Multiple Myeloma

NCT05847569 2026-02-03

Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma

62 enrolled

Multiple Myeloma

NCT04414475 2026-02-02

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

127 enrolled

Multiple Myeloma

NCT04240054 2026-01-28

VICD

41 enrolled

Multiple Myeloma, Renal Insufficiency

NCT06974786 2026-01-23

FASTER

Multiple Myeloma

NCT05922501 2026-01-14

ISABELA

50 enrolled

Multiple Myeloma, Recurrence

NCT06627751 2026-01-12

Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

28 enrolled

Multiple Myeloma

NCT05231629 2026-01-09

MASTER-2

300 enrolled

Multiple Myeloma

NCT06910124 2026-01-08

Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

32 enrolled

Multiple Myeloma

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

40 enrolled

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

90 enrolled